This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

New England Biolabs Opens Seventh Subsidiary In Singapore

IPSWICH, Mass., March 21, 2013 /PRNewswire/ -- New England Biolabs (NEB), a world leader in the production of reagents for the life science industry, extended its global subsidiary network with the opening of New England Biolabs Pte. Ltd., in Singapore.

(Logo:  http://photos.prnewswire.com/prnh/20090921/NE79207LOGO-b )

"The Singapore facility will provide the vibrant local scientific research community with more efficient access to the latest NEB products, technical support in the local time zone and languages, as well as OEM partnership opportunities," says Sue Yap, General Manager for the Singapore office.

Singapore, recently cited by Scientific American as the world's third most innovative country in biotech, is home to more than 5,000 life science researchers, numerous start-ups, and facilities for many of the largest pharmaceutical companies. Its significance to the biological sciences was reflected this past January, when the country hosted the inaugural Global Young Scientists Summit, featuring 12 Nobel Prize Laureates. Among these was the Chief Scientific Officer of NEB, Sir Richard Roberts, who conducted a seminar to inaugurate the opening of the NEB office.

" Singapore has a world class reputation in the life sciences. This new office will allow us to offer even greater personalized service and, when appropriate, to explore higher levels of collaboration, especially with the startup biotech companies now multiplying in Singapore," says Roberts.

NEB also maintains subsidiary offices in Canada, China, France, Germany, Japan, and the United Kingdom.

For more information, send e-mail to sales.sg@neb.com or telephone +65 67760903.

About New England Biolabs

Established in the mid 1970's, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, library preparation for next generation sequencing, cellular analysis, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and seven subsidiaries located in Canada, China, France, Germany, Japan, Singapore and the UK. For more information about New England Biolabs visit www.neb.com.

SOURCE New England Biolabs

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,721.47 +2.93 0.02%
S&P 500 2,057.20 -3.85 -0.19%
NASDAQ 4,863.7890 -12.73 -0.26%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs